CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at an average $35.11 ($7,022,668)
- 8-K Event Regulation FD disclosure
- 4 Shares withheld for taxes President & CIO gave up 19,976 shares (to pay taxes)
- 4 Shares withheld for taxes CEO gave up 34,638 shares (to pay taxes)
- 144 Insider Sale of Securities
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 4 Returned to the company Director returned 8,967,383 shares (to the company)
- 4 Planned sale Director sold 17,750 shares at an average $36.10 ($640,861)
- 4 Shares withheld for taxes CEO gave up 76,171 shares (to pay taxes)
- 4 Shares withheld for taxes President and Vant Chair gave up 40,309 shares (to pay taxes)
- 4 Shares withheld for taxes President & CIO gave up 46,879 shares (to pay taxes)
- 4 Planned sale President & Immunovant CEO sold 200,000 shares at $36.62 ($7,324,000)
- 144 Insider Sale of Securities
- 4 Shares withheld for taxes Chief Accounting Officer gave up 3,880 shares (to pay taxes)
- 4 Shares withheld for taxes CFO gave up 2,129 shares (to pay taxes)
- 4 Grant or award Director acquired 5,054 shares (grant or award)
- 4 Grant or award Director acquired 5,054 shares (grant or award)
- 4 Grant or award Director acquired 5,054 shares (grant or award)
- 4 Grant or award Director acquired 5,054 shares (grant or award)
- 4 Grant or award Director acquired 5,054 shares (grant or award)
Page 2 of 51 · 1,008 filings